Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ...
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an ...
Together, these data underscore the continued advancement of Immatics’ PRAME franchise and its focus on developing novel immunotherapies for patients with solid tumors. Full abstracts will be ...
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory phase I clinical study, the vaccine was well tolerated and generated ...
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone ...
TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026 TRIANA Biomedicines, Inc. (TRIANA), a ...
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), remains a significant global health burden with high morbidity and mortality. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results